Evidence map›Paper›PMID 27029671›Full record

ArticleInternational journal of circumpolar health2016

Results of interferon-based treatments in Alaska Native and American Indian population with chronic hepatitis C.

Stephen E Livingston, Lisa J Townshend-Bulson, Dana J T Bruden, Chriss E Homan, James E Gove, Julia N Plotnik, Brenna C Simons, Philip R Spradling, Brian J McMahon

Open access · goldAbstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of circumpolar health, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Infection With Hepatitis C Virus Genotype 3 Is an Independent Risk Factor for End-Stage Liver Disease, Hepatocellular Carcinoma, and Liver-Related Death.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2017
    Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Stephen E LivingstonLiver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, AK, USA.
Lisa J Townshend-BulsonLiver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, AK, USA.
Dana J T BrudenArctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Anchorage, AK, USA.
Chriss E HomanLiver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, AK, USA.
James E GoveLiver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, AK, USA.
Julia N PlotnikLiver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, AK, USA.
Brenna C SimonsLiver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, AK, USA.
Philip R SpradlingDivision of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Brian J McMahonLiver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, AK, USA.
Alaska Native Tribal Health Consortium · USCenters for Disease Control and Prevention · USNational Center for Emerging and Zoonotic Infectious Diseases · US

Funding

NATURAL HISTORY PREVENTION OF VIRAL HEPATITIS IN ALASKA NATIVE PEOPLEU01PS001097 · PS · ALASKA NATIVE TRIBAL HEALTH CONSORTIUM · PI MCMAHON, BRIAN JAMES · 2008 to 2012
$1.3M
Natural History and Prevention of Viral Hepatitis Among Alaska NativesU01PS004113 · PS · ALASKA NATIVE TRIBAL HEALTH CONSORTIUM · PI MCMAHON, BRIAN JAMES · 2013 to 2017
$897k
NCHHSTP CDC HHS U01 PS001097NCHHSTP CDC HHS U01 PS004113
6 · The paper itself

Abstract

backgroundThere have been few reports of hepatitis C virus (HCV) treatment results with interferon-based regimens in indigenous populations.

objectiveTo determine interferon-based treatment outcome among Alaska Native and American Indian (AN/AI) population.

designIn an outcomes study of 1,379 AN/AI persons with chronic HCV infection from 1995 through 2013, we examined treatment results of 189 persons treated with standard interferon, interferon plus ribavirin, pegylated interferon plus ribavirin and triple therapy with a protease inhibitor. For individuals treated with pegylated interferon and ribavirin, the effect of patient characteristics on response was also examined.

resultsSustained virologic response (SVR) with standard interferon was 16.7% (3/18) and with standard interferon and ribavirin was 29.7% (11/37). Of 119 persons treated with pegylated interferon and ribavirin, 61 achieved SVR (51.3%), including 10 of 46 with genotype 1 (21.7%), 38 of 51 with genotype 2 (74.5%) and 13 of 22 with genotype 3 (59.1%). By multivariate analysis, SVR in the pegylated interferon group was associated with female sex (p=0.002), estimated duration of infection (p=0.034) and HCV genotype (p<0.0001). There was a high discontinuation rate due to side effects in those treated with pegylated interferon and ribavirin for genotype 1 (52.2%). Seven of 15 genotype 1 patients treated with pegylated interferon, ribavirin and telaprevir or boceprevir achieved SVR (46.7%).

conclusionsWe had success with pegylated interferon-based treatment of AN/AI people with genotypes 2 and 3. However, there were low SVR and high discontinuation rates for those with genotype 1.

Indexed as

AdultAgedAlaskaAlaska NativesAntiviral AgentsDrug Therapy, CombinationFemaleFollow-Up StudiesHepacivirusHepatitis C, ChronicHumansIndians, North AmericanInterferon-alphaLongitudinal StudiesMaleMiddle AgedAntiviral AgentsInterferon-alphapeginterferon alfa-2aPolyethylene GlycolsRecombinant ProteinsRibavirindiscontinuationindigenous populationlongitudinal studypegylated interferonsustained virologic response

Identifiers

PMID27029671
PMCPMC4814572
OpenAlexW2320534176

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.